https://scholars.lib.ntu.edu.tw/handle/123456789/584496
標題: | Antimuscarinic Use in Females With Overactive Bladder Syndrome Increases the Risk of Depressive Disorder: A 3-Year Follow-up Study | 作者: | Chung S.-D. Weng S.-S. CHAO-YUAN HUANG Lin H.-C. Kao L.-T. |
關鍵字: | antimuscarinics; depressive disorder; muscarinic receptor antagonist; overactive bladder syndrome | 公開日期: | 2017 | 出版社: | Blackwell Publishing Inc. | 卷: | 57 | 期: | 8 | 起(迄)頁: | 1064-1070 | 來源出版物: | Journal of Clinical Pharmacology | 摘要: | To date, the relationship between antimuscarinics for overactive bladder (OAB) syndrome and depressive disorder still remains unclear. Therefore, this retrospective cohort study examined the association between antimuscarinic use and the subsequent risk of depressive disorder using a population-based data set. This study used data from the Taiwan Longitudinal Health Insurance Database 2005. We selected 1952 OAB women who received antimuscarinics as the study cohort and 9760 OAB women who did not receive antimuscarinics as the comparison cohort. Each subject was tracked for 3 years from her index date to determine all those who were subsequently diagnosed with depressive disorder. Results indicated that the adjusted hazard ratio (HR) for depressive disorder in OAB women who received antimuscarinics was 1.38 (95% confidence interval [CI], 1.15–1.64) compared with those OAB women who did not receive antimuscarinics. In addition, the adjusted HRs for subsequent depressive disorder for OAB women aged 18–39, 40–59, and ?60 years who received antimuscarinics were 1.83 (95%CI, 1.27–2.64), 1.36 (95%CI, 1.03–1.81), and 1.16 (95%CI, 0.86–1.56), respectively, compared with those OAB women who did not receive antimuscarinics. We concluded that women with OAB who received antimuscarinics had a significantly higher risk of subsequent depressive disorder compared with those OAB women who did not receive antimuscarinics. Accordingly, clinicians should be alert to the relationship between antimuscarinics usage and depressive disorder in OAB women and provide appropriate instructions for these patients. ? 2017, The American College of Clinical Pharmacology |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85017280092&doi=10.1002%2fjcph.890&partnerID=40&md5=648ab0296486971f8018a8e19010e718 https://scholars.lib.ntu.edu.tw/handle/123456789/584496 |
ISSN: | 0091-2700 | DOI: | 10.1002/jcph.890 | SDG/關鍵字: | oxybutynin; propiverine; solifenacin; tolterodine; trospium chloride; muscarinic receptor blocking agent; adult; age; aged; cohort analysis; controlled study; depression; drug use; female; follow up; human; incidence; major clinical study; overactive bladder; prescription; retrospective study; Review; Taiwan; adolescent; depression; middle aged; overactive bladder; risk; young adult; Adolescent; Adult; Aged; Depressive Disorder; Female; Follow-Up Studies; Humans; Middle Aged; Muscarinic Antagonists; Retrospective Studies; Risk; Taiwan; Urinary Bladder, Overactive; Young Adult |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。